Scrip
Genta assesses direction after disappointing melanoma trial
02 November 2009
Malini Guha
Genta's troubled novel antisense lead drug candidate Genasense (oblimersen sodium) has failed to meet one of its primary endpoints, progression-free survival (PFS), in a pivotal, first-line Phase III AGENDA trial in advanced melanoma. The company said it was assessing the impact of these data – which...
Please Login to read the full article.
02 November 2009
Malini Guha
Please Login to read the full article.
RELATED CONTENT
NEWS
- Vectibix clears PFS but survival hurdle still awaits in colorectal cancer
- Amgen's Vectibix fails to show survival benefit in pivotal first-line trial in colorectal cancer
- Vectibix fails pivotal trial in head and neck cancer
- Genmab's zalutumumab fails Phase III trial in refractory head and neck cancer
COMMENT
Other Informa Comment
FEATURES
- Roche's Asian partnering head looks to tap regional innovation
- GE Healthcare aims to end unpredictability in early drug research
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
